Clinical Trial: A Phase I, First-in-Human Study of GB268 (PD-1/CTLA-4/VEGF Trispecific Antibody) in Participants With Advanced Solid Tumors

U.S., April 19 -- ClinicalTrials.gov registry received information related to the study (NCT06934616) titled 'A Phase I, First-in-Human Study of GB268 (PD-1/CTLA-4/VEGF Trispecific Antibody) in Participants With Advanced Solid Tumors' on March 16.

Brief Summary: This is a Phase I, First-in-Human, Open-Label, Multicenter Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of a Trispecific PD-1/CTLA-4/VEGF Antibody GB268 in Participants with Advanced Solid Tumors. The study will consist of a dose-escalation stage and an dose-expansion stage.

Study Start Date: April 24

Study Type: INTERVENTIONAL

Condition: Solid Tumor Cancer

Intervention: DRUG: GB268

GB268 will be administered via intravenous infusion once every 3 ...